TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: IPT in Schoolchildren: Comparison of the Efficacy, Safety, and Tolerability of Antimalarial Regimens in Uganda
Brief Summary: This will be a randomized, single-blinded, placebo-controlled trial to evaluate the efficacy, safety and tolerability of antimalarial regimens in healthy schoolchildren. The primary objective of the study is to compare the efficacy of different combination antimalarial regimens, including amodiaquine + sulfadoxine-pyrimethamine (AQ+SP), dihydroartemisinin-piperaquine (DP), and placebo, to SP for intermittent preventive treatment (IPT) in schoolchildren, as measured by risk of parasitaemia (unadjusted by genotyping) after 42 days of follow-up. This will assess both the efficacy for treatment of asymptomatic infections and the efficacy for prevention of new infections.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Seasonal IPT in children - Sulfadoxine-pyrimethamine | Intervention Type: DRUG; Name: Seasonal IPT in children - Sulfadoxine-pyrimethamine; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: sulfadoxine /pyrimethamine plus amodiaquine; Assigned to Arm(s): N/A
C: Arm Label: Combination of Amodiaquine +sulfadoxine-pyrimethamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: amodiaquine + sulfadoxine-pyrimethamine | Arm Label: Dihydroartemisinin-piperaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Sulfadoxine-pyrimethamine alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfadoxine-pyrimethamine | Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): Sulfadoxine-pyrimethamine alone | Intervention Type: DRUG; Name: amodiaquine + sulfadoxine-pyrimethamine; Assigned to Arm(s): Combination of Amodiaquine +sulfadoxine-pyrimethamine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine; Assigned to Arm(s): Dihydroartemisinin-piperaquine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Pyrimethamine/sulfadoxine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amodiaquine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria
Brief Summary: Malaria is the most important human parasitic disease and is responsible of high morbidity and mortality in resource-poor countries. Pregnant women, who are a high-risk group, are almost always excluded from clinical trials; thus, the investigators lack sufficient information on the safety and efficacy of most antimalarials in pregnancy. The recommendation of the World Health Organization to use artemisinin combination therapy (ACT) in the 2nd and 3rd trimester is already implemented in several African countries, however documentation of their efficacy and safety in pregnancy is still limited. Thus, the investigators propose to evaluate the efficacy and safety of 4 ACT(artemether-lumefantrine, amodiaquine-artesunate, mefloquine-artesunate and dihydroartemisinin-piperaquine), when used to treat pregnant women with P. falciparum malaria; the results will help to recommend the optimal therapy for this high-risk group in Africa.


Options:
A: Arm Label: DHAPQ; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-piperaquine | Arm Label: MQAS; Type: EXPERIMENTAL; Interventions: Drug: Artesunate-mefloquine | Arm Label: AQAS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate-amodiaquine | Arm Label: AL; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine | Intervention Type: DRUG; Name: Dihydroartemisinin-piperaquine; Assigned to Arm(s): DHAPQ | Intervention Type: DRUG; Name: Artesunate-mefloquine; Assigned to Arm(s): MQAS | Intervention Type: DRUG; Name: Artesunate-amodiaquine; Assigned to Arm(s): AQAS | Intervention Type: DRUG; Name: Artemether-lumefantrine; Assigned to Arm(s): AL
B: Arm Label: Trial 1: IPTp-SP+LLITNs; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine | Arm Label: Trial 1: IPTp-MQ (full dose) + LLITNs; Type: EXPERIMENTAL; Interventions: Drug: Mefloquine (full dose) | Arm Label: Trial 1: IPTp-MQ (split dose)+LLITNs; Type: EXPERIMENTAL; Interventions: Drug: Mefloquine (split dose) | Arm Label: Trial 2: CTX+IPTp-Placebo+LLITNs; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: Trial 2: CTX + IPTp-MQ+ LLITNs; Type: EXPERIMENTAL; Interventions: Drug: mefloquine | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine; Assigned to Arm(s): Trial 1: IPTp-SP+LLITNs | Intervention Type: DRUG; Name: Mefloquine (full dose); Assigned to Arm(s): Trial 1: IPTp-MQ (full dose) + LLITNs | Intervention Type: DRUG; Name: Mefloquine (split dose); Assigned to Arm(s): Trial 1: IPTp-MQ (split dose)+LLITNs | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Trial 2: CTX+IPTp-Placebo+LLITNs | Intervention Type: DRUG; Name: mefloquine; Assigned to Arm(s): Trial 2: CTX + IPTp-MQ+ LLITNs
C: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine / mefloquine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Sulfadoxine-Pyrimethamine (Fansidar); Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: ITNs; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria
Brief Summary: Malaria is the most important human parasitic disease and is responsible of high morbidity and mortality in resource-poor countries. Pregnant women, who are a high-risk group, are almost always excluded from clinical trials; thus, the investigators lack sufficient information on the safety and efficacy of most antimalarials in pregnancy. The recommendation of the World Health Organization to use artemisinin combination therapy (ACT) in the 2nd and 3rd trimester is already implemented in several African countries, however documentation of their efficacy and safety in pregnancy is still limited. Thus, the investigators propose to evaluate the efficacy and safety of 4 ACT(artemether-lumefantrine, amodiaquine-artesunate, mefloquine-artesunate and dihydroartemisinin-piperaquine), when used to treat pregnant women with P. falciparum malaria; the results will help to recommend the optimal therapy for this high-risk group in Africa.


Options:
A: Arm Label: Trial 1: IPTp-SP+LLITNs; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine | Arm Label: Trial 1: IPTp-MQ (full dose) + LLITNs; Type: EXPERIMENTAL; Interventions: Drug: Mefloquine (full dose) | Arm Label: Trial 1: IPTp-MQ (split dose)+LLITNs; Type: EXPERIMENTAL; Interventions: Drug: Mefloquine (split dose) | Arm Label: Trial 2: CTX+IPTp-Placebo+LLITNs; Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: Trial 2: CTX + IPTp-MQ+ LLITNs; Type: EXPERIMENTAL; Interventions: Drug: mefloquine | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine; Assigned to Arm(s): Trial 1: IPTp-SP+LLITNs | Intervention Type: DRUG; Name: Mefloquine (full dose); Assigned to Arm(s): Trial 1: IPTp-MQ (full dose) + LLITNs | Intervention Type: DRUG; Name: Mefloquine (split dose); Assigned to Arm(s): Trial 1: IPTp-MQ (split dose)+LLITNs | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Trial 2: CTX+IPTp-Placebo+LLITNs | Intervention Type: DRUG; Name: mefloquine; Assigned to Arm(s): Trial 2: CTX + IPTp-MQ+ LLITNs
B: Arm Label: DHAPQ; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisinin-piperaquine | Arm Label: MQAS; Type: EXPERIMENTAL; Interventions: Drug: Artesunate-mefloquine | Arm Label: AQAS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate-amodiaquine | Arm Label: AL; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine | Intervention Type: DRUG; Name: Dihydroartemisinin-piperaquine; Assigned to Arm(s): DHAPQ | Intervention Type: DRUG; Name: Artesunate-mefloquine; Assigned to Arm(s): MQAS | Intervention Type: DRUG; Name: Artesunate-amodiaquine; Assigned to Arm(s): AQAS | Intervention Type: DRUG; Name: Artemether-lumefantrine; Assigned to Arm(s): AL
C: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine / mefloquine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Sulfadoxine-Pyrimethamine (Fansidar); Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: ITNs; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Restrictive Versus Liberal Intraoperative Goal-directed Fluid Management During Major Abdominal Surgery:a Prospective Randomized Study
Brief Summary: Postoperative organ dysfunction severely affects the prognosis of surgical patients. Despite several trials evaluating restrictive or liberal fluid strategies, the ideal fluid replacement strategy remains controversial. Owing to the risk of altered tissue perfusion, a key trigger of organ dysfunction, the purpose of this study was to compare the influence of restrictive and liberal fluid regimens, using a goal-directed approach, on hypovolemia and postoperative organ dysfunction.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Procedure: Standard Care | Arm Label: 2; Type: OTHER; Interventions: Procedure: Fast Track care | Intervention Type: PROCEDURE; Name: Standard Care; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Fast Track care; Assigned to Arm(s): 2
B: Arm Label: Standard fluid management; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard fluid management | Arm Label: Goal directed fluid therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Goal directed fluid therapy with the Edwards EV1000 system | Intervention Type: PROCEDURE; Name: Standard fluid management; Assigned to Arm(s): Standard fluid management | Intervention Type: DEVICE; Name: Goal directed fluid therapy with the Edwards EV1000 system; Assigned to Arm(s): Goal directed fluid therapy
C: Arm Label: Goal directed fluid therapy using esophageal doppler monitor; Type: ACTIVE_COMPARATOR; Interventions: Device: Esophageal Doppler Monitor | Arm Label: Fluid therapy using standard management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Esophageal Doppler Monitor; Assigned to Arm(s): Goal directed fluid therapy using esophageal doppler monitor
D: Arm Label: restrictive fluid; Type: EXPERIMENTAL; Interventions: Other: restrictive and liberal fluid therapy | Arm Label: liberal fluid; Type: EXPERIMENTAL; Interventions: Other: restrictive and liberal fluid therapy | Intervention Type: OTHER; Name: restrictive and liberal fluid therapy; Assigned to Arm(s): liberal fluid, restrictive fluid

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Macrolides on Asthma Control, Airway Inflammation and Bacterial Colonisation in Smokers With Asthma.
Brief Summary: Asthma is a common disease in Westernised societies, affecting up to 10% of the population. Corticosteroids are the most effective treatment for asthma but the therapeutic response varies considerably between individuals. A major cause of corticosteroid insensitivity in asthma is cigarette smoking. Active cigarette smoking occurs in over 25% of adults with asthma and a further 25% are ex-smokers. In a series of proof of concept clinical studies the investigators demonstrated for the first time that the efficacy of inhaled and oral corticosteroids is markedly impaired in smokers with asthma and to a lesser extent in ex-smokers with asthma. Active cigarette smoking has other detrimental effects on asthma morbidity including more severe symptoms, increased rates of hospitalisation, and accelerated decline in lung function. Smoking cessation advice is often ineffective because many adult smokers with asthma do not believe that they are personally at risk from their smoking, take many years until stopping smoking and frequently restart smoking after quitting. Alternative or additional drugs to corticosteroids are needed for smokers with asthma who are unable to obtain the clinical benefits associated with stopping smoking. In a proof of concept clinical trial the investigators will test the hypothesis that macrolides improve asthma control and reduce sputum neutrophil counts of smokers with chronic asthma.


Options:
A: Arm Label: Azithromycin (Zithromax); Type: EXPERIMENTAL; Interventions: Drug: Zithromax | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zithromax; Assigned to Arm(s): Azithromycin (Zithromax) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Antibiotics; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo mixture | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Antibiotics | Intervention Type: OTHER; Name: Placebo mixture; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Telithromycin; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Macrolides on Asthma Control, Airway Inflammation and Bacterial Colonisation in Smokers With Asthma.
Brief Summary: Asthma is a common disease in Westernised societies, affecting up to 10% of the population. Corticosteroids are the most effective treatment for asthma but the therapeutic response varies considerably between individuals. A major cause of corticosteroid insensitivity in asthma is cigarette smoking. Active cigarette smoking occurs in over 25% of adults with asthma and a further 25% are ex-smokers. In a series of proof of concept clinical studies the investigators demonstrated for the first time that the efficacy of inhaled and oral corticosteroids is markedly impaired in smokers with asthma and to a lesser extent in ex-smokers with asthma. Active cigarette smoking has other detrimental effects on asthma morbidity including more severe symptoms, increased rates of hospitalisation, and accelerated decline in lung function. Smoking cessation advice is often ineffective because many adult smokers with asthma do not believe that they are personally at risk from their smoking, take many years until stopping smoking and frequently restart smoking after quitting. Alternative or additional drugs to corticosteroids are needed for smokers with asthma who are unable to obtain the clinical benefits associated with stopping smoking. In a proof of concept clinical trial the investigators will test the hypothesis that macrolides improve asthma control and reduce sputum neutrophil counts of smokers with chronic asthma.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Azithromycin and Placebo for Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo for Azithromycin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin and Placebo for Azithromycin | Intervention Type: DRUG; Name: Placebo for Azithromycin; Assigned to Arm(s): Placebo for Azithromycin
C: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Computerized Assessment for Patients With Cancer-ESRA-C II
Brief Summary: This research study will test a new online computer program for patients, the Electronic Self-Report Assessment-Cancer (ESRA-C 2). The program allows patients to report symptoms and quality of life issues and learn information about how to deal with these experiences. The computer program is being tested to see if it can improve communications between patients and their care team and if it can improve patients' experiences during and after treatment.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Electronic Self-Report Assessment - Cancer (ESRA-C) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Electronic Self-Report Assessment - Cancer (ESRA-C); Assigned to Arm(s): Intervention
B: Arm Label: Electronic monitor + no text message; Type: PLACEBO_COMPARATOR; Interventions: Device: Electronic + no text message | Arm Label: Electronic monitor + Text message; Type: EXPERIMENTAL; Interventions: Device: Electronic monitor + text messages | Intervention Type: DEVICE; Name: Electronic + no text message; Assigned to Arm(s): Electronic monitor + no text message | Intervention Type: DEVICE; Name: Electronic monitor + text messages; Assigned to Arm(s): Electronic monitor + Text message
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Check Your Drinking University version | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Check Your Drinking University version; Assigned to Arm(s): Intervention
D: Arm Label: Mood monitoring; Type: EXPERIMENTAL; Interventions: Device: Mobile Tracking Young People's Experiences (mobiletype) | Arm Label: Comparison monitoring program; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Mobile Tracking Young People's Experiences (mobiletype); Assigned to Arm(s): Mood monitoring

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Randomized, Double Blind, Placebo Controlled Dose Finding Study Investigating the Efficacy of HP802-247 in Venous Leg Ulcers
Brief Summary: This is a 16-week study for subjects with a venous leg ulcer between the knee and ankle. This research is being done to determine the effectiveness of two dosing frequencies and two different concentrations of HP802-247, together with standard care, compared to placebo, plus standard care.


Options:
A: Arm Label: A - Low Q7D; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: B - Low Q14D; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: C - High Q7D; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: D - High Q14D; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: E - Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (Vehicle) | Intervention Type: BIOLOGICAL; Name: HP802-247; Assigned to Arm(s): A - Low Q7D, B - Low Q14D, C - High Q7D, D - High Q14D | Intervention Type: BIOLOGICAL; Name: Placebo (Vehicle); Assigned to Arm(s): E - Vehicle
B: Arm Label: Keratin dressings; Type: EXPERIMENTAL; Interventions: Device: Keratin dressings | Arm Label: Usual care dressings; Type: ACTIVE_COMPARATOR; Interventions: Device: Usual care dressings | Intervention Type: DEVICE; Name: Keratin dressings; Assigned to Arm(s): Keratin dressings | Intervention Type: DEVICE; Name: Usual care dressings; Assigned to Arm(s): Usual care dressings
C: Arm Label: HP802-247; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Biological: Vehicle | Intervention Type: BIOLOGICAL; Name: HP802-247; Assigned to Arm(s): HP802-247 | Intervention Type: BIOLOGICAL; Name: Vehicle; Assigned to Arm(s): Vehicle
D: Arm Label: HP802-247 plus compression therapy; Type: EXPERIMENTAL; Interventions: Biological: HP802-247 | Arm Label: HP802-247 Vehicle plus compression therapy; Type: PLACEBO_COMPARATOR; Interventions: Other: HP802-247 Vehicle | Intervention Type: BIOLOGICAL; Name: HP802-247; Assigned to Arm(s): HP802-247 plus compression therapy | Intervention Type: OTHER; Name: HP802-247 Vehicle; Assigned to Arm(s): HP802-247 Vehicle plus compression therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Brief Summary: This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background methotrexate in patients with Rheumatoid Arthritis. The study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day on background methotrexate in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in Rheumatoid Arthritis. An active comparator, adalimumab, is also included.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3
B: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol
C: Arm Label: 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 | Arm Label: 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biologic TNFi | Intervention Type: DRUG; Name: CP 690,550; Assigned to Arm(s): 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 10 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2 | Intervention Type: BIOLOGICAL; Name: Biologic TNFi; Assigned to Arm(s): adalimumab
D: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A

Answer: C